Despite the numerous advances in DM therapies in the last decade, few changes have been noted in overall glycemic control [3]. Recent consensus guidelines state that glycosylated hemoglobin (HbA1c) levels should be achieved as close to normal (~5.0%) as possible but should definitely be targeted to <7.0%. Historically, continuous glucose monitoring (CGM) allows providers and/or patients to identify blood glucose trends and rates of glucose change, and have more recently been shown to decrease HbA1c values while preventing the severity and time spent in hyperglycemic and hypoglycemic ranges.